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This study has tested the hypothesis that comparison of protein and mRNA expression for ERa and ERb1 by human breast cancers
provides novel information relating to the clinical and pathological characteristics of human breast cancers. Expression of ERa and
ERb1 was identified in 167 invasive cancers from postmenopausal women treated only with endocrine therapy. The cohort included
143 cases receiving only adjuvant Tamoxifen following surgery. ERa and ERb1 expression was analysed by immunohistochemistry and
reverse transcription RT–PCR and compared with clinical progression of individual cancers. ERa protein was closely associated with
the corresponding RNA detected by RT–PCR (Chi-square, Po0.001). In contrast, ERb1 protein and mRNA were inconsistent.
Although an association was identified between ERa and ERb mRNAs (Chi-square, Po0.001) and between ERa protein and ERb1
mRNA (Chi-square, Po0.027), no association was identified for the ERa and ERb1 proteins detected by immunohistochemistry.
ERb1 was not associated with outcome. However, in the absence of ERa,E R b1 protein expression was associated with elevated cell
proliferation. There was a trend for the ERb1 protein-positive cases to have a worse outcome, both within the group as a whole as
well as within the ERa-positive Tamoxifen-treated cases. This study has confirmed the hypothesis that expression of ERa is an
important determinant of breast cancer progression, and has further demonstrated that ERb1 may play a role in the response of
breast cancers to endocrine therapy.
British Journal of Cancer (2004) 91, 1694–1702. doi:10.1038/sj.bjc.6602183 www.bjcancer.com
Published online 12 October 2004
& 2004 Cancer Research UK
Keywords: breast cancer; ER gene expression; tamoxifen; oestrogen receptor beta; tumour progression
                                                 
Currently, ERa expression is regarded as a reliable prognostic
marker with which to predict the response of an individual breast
cancer to hormone therapy (Pertschuk and Axiotis, 1999).
However, up to 40% of breast tumours with positive ERa status
do not respond to endocrine manipulation (Locker, 1998). The
biological basis of this failure to respond is poorly understood,
although modulated expression of ERb has been implicated. Unlike
ERa, the antioestrogen–ERb complex inhibits gene transcription
when bound to oestrogen response elements (EREs), but acts as an
agonist when bound to AP1 elements (Paech et al, 1997). Therefore,
it is possible that antioestrogens may have agonistic effects in ERb-
positive breast tumours, resulting in a lack of efficacy of hormonal
therapy. This hypothesis is supported by a small number of cases in
which overexpression of ERb RNA has been found in Tamoxifen-
resistant tumours (n¼9) when compared with a Tamoxifen-
sensitive group (n¼8) (Speirs et al, 1999), but refuted by an
immunohistochemical study (Mann et al, 2001) of ERb protein in a
larger group (n¼118). Hitherto, only a limited number of studies
have used ERb-specific antibodies (Jarvinen et al, 2000; Omoto et al,
2001; Saunders et al, 2002). These have been based on relatively
small numbers of unselected cases and do not all address the
relationship of ERb1 expression with patient outcome. Similarly,
there are limited studies addressing the specific relationship of ERb
with endocrine therapy (Speirs et al, 1999; Mann et al, 2001; Saji
et al, 2002). Hence, the present study has been restricted to an
assessment of postmenopausal women receiving endocrine therapy,
but no chemotherapy, in order to better address the likely impact of
ERb1 expression on response in this common clinical setting.
Recent development of reliable antibodies to ERb, as well as to
ERa, has allowed examination of the protein expression of these
genes (Taylor and Al-Azzawi, 2000; Choi et al,2 0 0 1 ;M a n net al,
2001; Miyoshi et al, 2001; Omoto et al, 2001; Roger et al, 2001; Skliris
et al, 2001, 2002; Saji et al, 2002; Saunders et al, 2002). One previous
report suggested a lack of correlation between mRNA and protein
for total ERb in 37 out of 61 tumours studied (Shaw et al, 2002).
Consequently, there is a lack of available data on the possible
significance of ERb expression in specific treatment cohorts.
Furthermore, many previous studies have not adequately defined
the precise ERb variants being measured or have used antibodies
capable of detecting multiple variants (Skliris et al,2 0 0 3 ) .T h e
relatively high levels of ERb1 protein identified in positive cases may
indicate that the PPG5/10 antibody, employed in this study, is among
the most sensitive presently available for use in immunohistochem-
istry (Skliris et al, 2002) with the protocol employed herein (Shaaban
et al, 2003a). Using this antibody, we have already confirmed that the
level of ERb1 detected in normal breast epithelium and in
premalignant breast lesions is greater than formerly recognised
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y(Shaaban et al, 2003a,b). Therefore, the purpose of this study was to
test the hypothesis that comparison of protein expression levels of
ERa and ERb1, together with their respective mRNA levels, in a
cohort of postmenopausal primary breast cancer patients treated
with surgery and hormonal therapy, would accurately predict the
clinical and pathological characteristics of these cancers.
MATERIALS AND METHODS
Patients
Patients undergoing treatment for invasive breast cancer during
the period 1993–1999 were identified within the archival database
of the Department of Pathology at the Royal Liverpool University
Hospital, and the Cancer Tissue Bank Research Centre (CTBRC) in
the same institution. The study population comprised a group of
167 postmenopausal women treated with surgery either with, or
without, radiation treatment (Table 1). All patients received
adjuvant hormone therapy but no chemotherapy. For 143 cases,
endocrine therapy consisted of adjuvant Tamoxifen only. Since
steroid receptor analysis was not routinely performed until 1996,
some cases were subsequently found to be ERa-negative. All cases
were subjected to full histopathological review, by three investi-
gators (PAO0N, CSF and JPS) according to the UK NHSBSP
guidelines (National Coordinating Group for Breast Screening,
1997). Clinical follow-up data, with informed consent, were
recorded by retrospective case-note review. Ethical approval for
the study was obtained from all relevant bodies.
Immunohistochemistry
Mouse anti-(human ERb1) monoclonal antibody PPG5/10 was
employed to recognise the ERb1 isoform (Serotec Ltd, Kidlington,
Oxford, UK). Specificity of the antibody has previously been
confirmed by Western blotting in our laboratory (Shaaban et al,
2003b). For the immunohistochemical detection of ERa, a mouse
anti-(human ERa) monoclonal antibody was used (Clone 1D5,
Dako Ltd, Ely, Cambridge, UK). Progesterone receptor (PgR)
status was measured using a mouse monoclonal anti-PgR antibody
(Clone 1A6, Novacastra, Newcastle upon Tyne, UK). Ki67 status
was assessed using polyclonal rabbit anti-human Ki67 antibody
(Ki67p, Novacastra, Newcastle upon Tyne, UK).
Formalin-fixed and paraffin wax-embedded sections of normal,
benign and malignant breast tissues were immunostained for ERa
and ERb1. The methods were identical to those previously
described (Shaaban et al, 2002), but with the addition of an
overnight incubation at 41C for the ERb1 antibody diluted (1:2) in
Tris buffer (pH 7.2) containing 1% (w/v) BSA. Immunostaining for
ERa was performed by incubating sections with the mouse anti-
ERa monoclonal antibody for 40min at room temperature.
Positive and negative controls were included for each antibody
and in each batch of staining.
Analysis was restricted to the epithelial component of all tissues.
To maximise consistency of scoring, only nuclei having moderate
or strong staining were regarded as positive, irrespective of
cytoplasmic staining. The percentage of positively stained
epithelial cells was calculated as a proportion of the total number
of epithelial cells present. For ERb1, cases were considered as
positive only when more than 20% of cells were stained, as
previously described (Jarvinen et al, 2000; Miyoshi et al, 2001;
Shaaban et al, 2003b), although other cutoff values were also
tested. In contrast with ERa, there has been no agreement on the
cutoff value for defining ERb positivity. We chose a cutoff value of
20% as previously described in the studies by Jarvinen et al (2000)
and Miyoshi et al (2001), as well as to be consistent with our
previous study (Jarvinen et al, 2000; Miyoshi et al, 2001; Shaaban
et al, 2003b). A 10% cutoff (consistent with that employed in our
previous studies) was applied as the conventional criterion to
define positive ERa or PgR staining (Sannino and Shousha, 1994).
Ki67 was regarded as elevated if 420% cells were stained, based on
the median expression in this cohort of cases.
Reverse transcription (RT)–PCR analysis
Total RNA (5mg) was provided by the CTBRC. Following DNAaseI
digestion (Gibco), RT was performed in duplicate on 0.5mgo f
RNA, according to the manufacturers’ instructions (Gibco).
Reverse transcription reactions incorporated Superscript II
Reverse Transcriptase (Gibco), 0.5mg Oligo (dT)12 18 and 0.5ml
Prime Recombinant Ribonuclease Inhibitor (Eppendorf). Parallel
reactions were performed in which the RT enzyme was omitted
and these acted as controls for genomic DNA contamination.
Polymerase chain reactions were performed in 20ml duplicate
volumes in 96-well plates, each using 2ml of a 1/20 dilution of
cDNA per reaction (equivalent to cDNA from approximately 2.5ng
of total RNA). All PCR reactions included 0.2mM dNTPs, 0.5U of
HotstarTaq DNA polymerase (Qiagen) and 1  PCR buffer
(containing 1.5mM MgCl2, Qiagen). Oligonucleotide primers for
RT–PCR and the conditions used are shown in Table 2 and have
been previously validated (Moore et al, 1998; Kurebayashi et al,
2000). Primer concentrations and final MgCl2 concentrations
varied according to Table 2. The PCR reaction used for ERb is
specific for the ERb1 isoform (Moore et al, 1998). b-Actin and
hypoxanthine ribosyltransferase (HPRT) were used as control
genes to determine RNA integrity and RT efficiency. Care was
taken to ensure that each PCR reaction was limited in cycle
number, thus to avoid the plateau phase of the reaction. Oestrogen
receptor a RNA was assessed both by ERa PCR and duplex PCR for
ERa and actin primers (Kurebayashi et al, 2000). The data were
Table 1 Histological, clinical and molecular characteristics of 167 breast
cancer cases receiving adjuvant endocrinetreatment but no chemotherapy
Characteristic Group n%
Histology Invasive ductal 141 84
n¼167 Invasive lobular 13 8
Other 13 8
Surgery Wide local excision 104 62
n¼167 Mastectomy 63 38
Endocrine therapy Tamoxifen adjuvant only 143 86
Other adjuvant only 7 4
n¼167 Primary and adjuvant 17 10
Radiotherapy No 89 53
n¼167 Yes 78 47
Stage I 38 23
n¼167 II 93 56
III 7 4
Grade I 26 16
n¼167 II 65 39
III 76 46
Size Up to 2cm 67 40
n¼165 42 to 5cm 98 59
Nodal status Negative 73 44
n¼167 Positive 64 38
Lymphovascular invasion Negative 95 57
Positive 71 43
n¼166
PgR status Negative 84 57
n¼147 Positive 63 43
Ki67 status Negative 72 51
n¼142 Positive 70 49
ERa status Negative 53 33
n¼160 Positive 107 67
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yhighly concordant (Chi-square, Po0.001). Polymerase chain
reactions for ERb, actin and HPRT were performed individually.
Positive controls using MCF-7 cell line cDNA for ERa and testis
cDNA for ERb1 were included together with negative controls in
each reaction plate. Polymerase chain reaction was performed
using Perkin-Elmer 9600 thermal cyclers. All cycling reactions
were preceded by a pre-incubation at 941C for 13min, and were
followed within a 3min final extension at 721C. Cycling conditions
for reactions are given in Table 3.
Polymerase chain reaction products were separated by electro-
phoresis on gels containing 2.5% Seakem Agarose (Flowgen) and
TAE buffer (40mM Tris acetate, 1mM EDTA, pH 7.6). Molecular
weight markers (PhiX174/HaeIII, Abgene) were included on each
gel and DNA was visualised by inclusion of 0.5mgml
 1 ethidium
bromide, scanning with a Molecular Dynamics FluorimagerSI and
analysis with ImageQuant version 4.1 software (Molecular
Dynamics).
The identity of PCR products was confirmed by direct
sequencing using DYEnamic ET Dye Terminator Cycle Sequencing
Kit for MegaBACE (Amersham Pharmacia Biotech) and analysed
on a MegaBACE 1000 (Molecular Dynamics). Alternatively, PCR
products were cloned using TOPO-TA cloning (Invitrogen) prior
to sequence analysis.
The presence of a PCR product was assessed independently by
two investigators (PAO0N and MPAD) and scored as positive
where both agreed. Control genes, actin and HPRT were scored as
weak or strong positive and individual RT reactions excluded from
ER assessment if either gene was negative, or if both were only
weak. Cases were considered positive for ERa or ERb if any band
was seen regardless of the intensity.
Statistical analysis
All statistical analyses were performed using the SPSS
s package
(Windows, v.11). To compare the immunohistochemical percen-
tage values for ERa, PgR, Ki67 or ERb1 in different groups, data
were analysed by the nonparametric, two-sided Mann–Whitney
test and the two-sided T-test. The nonparametric, two-sided
Mann–Whitney test was also used for other ordinal data such as
stage and grade. Association between categorical data was assessed
by the Chi-squared test and correlations between interval data
were tested using Pearson’s correlation coefficient. Survival curves
were generated using the Kaplan–Meier method for censored data
and compared using the log-rank test. Cox’s regression models
were used for multivariate survival analysis.
RESULTS
RT–PCR
The identities of representative RT–PCR products for each gene
were confirmed by sequence analysis. No evidence of artefactual
PCR products due to genomic DNA contamination was identified.
An example of RT–PCR analysis is shown in Figure 1. The use of
control genes b-actin and HPRT identified 127 cases in which
cDNA was considered to be of appropriate quantity and integrity
for further analysis. The results of these two control genes were in
agreement (Chi-square 27, Po10
 6). Reverse transcription–PCR
analysis categorised 66% cases as ERa-positive and 68% cases as
ERb1-positive (Table 4). In all, 51% were positive for both ERa and
ERb1, 18% negative for both, 17% positive only for ERa and 14%
positive only for ERb1. There was some association between RT–
PCR results for each ER (Chi-square 12.3, Po0.0005). The
distribution of ERb-positive tumours was significantly different
between ERa-positive and -negative cases.
Immunohistochemistry
Immunostaining for ERa was performed on 149 cases and was
nuclear in all cases regarded as positive. Cytoplasmic-only staining
was excluded. Cytoplasmic staining for ERb has been described in
several studies and is likely to be genuine and not a staining
artefact, although the precise significance of cytoplasmic staining
remains unknown. Similar to ERa, cytoplasmic staining without
nuclear expression was considered negative, so that only nuclear
expression was interpreted as positive to maintain convention and
comparability with previously reported studies. Using a cutoff
value of 10%, 49 cases (33%) were ERa-negative by immunohis-
tochemistry and the remaining 100 cases (67%) classed as ERa-
positive. Oestrogen receptor a status was available for a further 11
cases by case-note review (Table 1). Conventionally, the epithelial
component only was scored on assessing ERa and ERb positivity.
Oestrogen receptor a was expressed in the epithelial cells, but ERb
was also expressed in the stroma.
Immunostaining for ERb1 was performed on 138 cases.
Epithelial cells were considered positive if nuclear staining was
identified (Figure 2). Cytoplasmic staining co-existent with nuclear
staining was identified in 64 cases (Figure 2). In contrast with ERa,
there has been no agreement on the cutoff value for defining ERb
positivity. The conventional cutoff value for ERa positivity is 10%
(Sannino and Shousha, 1994). We used a cutoff value of 20% as
Table 2 Primer sequences, conditions, and product sizes in base pairs (bp) for RT–PCR
PCR Primer sequence [Primer] (lM)[ M g C l 2]( m M) Size (bp)
ERa AGACATGAGAGCTGCCAACC 2 1.5 299
GCCAGGCACATTCTAGAAGG
ERb1 CCAAATGAGGGACCACACAGCAG 1 1.5 476
AGTATGTACCTCTGGTCACAGCG
b-actin TGACGGGGTCACCCACACTGTGCCCATCTA 0.48 1.5 610
CTAGAAGCATTTGCGGTGGACGATGGAGGG
HPRT CTATTGTAATGACCAGTCAACAGGGG 1 3 367
AACTCAACTTGAACTCTCATCTT
Table 3 Conditions of sequence-specific PCR cycling reactions
Condition
Oligonucleotide Cycle
Denaturation
phase
Annealing
phase
Extension
phase
ERa and b-actin 35 941C, 15s 581C, 15s 721C, 30s
ERb14 0 9 4 1C, 30s 641C, 40s 721C, 45s
HPRT 36 941C, 30s 601C, 60s —
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ypreviously used in the studied by Jarvinen et al (2000) and Miyoshi
et al (2001), as well as to be consistent with our previous study
(Shaaban et al, 2003b). The 20% cutoff (Jarvinen et al, 2000;
Miyoshi et al, 2001; Shaaban et al, 2003b) for ERb1 staining
resulted in a high proportion of positive cases (85%, 118 cases).
The mean percentage of stained cells was 14% for negative cases
and 69% for positive cases (T-test, Po0.0005). The proportion of
immunostained cancer cells was considerably more variable for
ERb1 than for ERa (Figure 3).
Immunohistochemical data for both ERa and ERb1 were
available for 137 cases. In all, 56% of all cases were positive for
both ERs (Table 4) and only 3% were negative for both ERa and
ERb1. However, a significant proportion (29%) was negative for
ERa but expressed ERb1, compared to a smaller number of cases
expressing ERa alone (12%). There was no significant association
between ERa and ERb1 status (Chi-square 1.6, P¼0.21). No
correlation between the proportion of immunopositive cells was
identified (Pearson’s R¼ 0.007, P¼0.94).
Relationship between ER RT–PCR and
immunohistochemistry
Reverse transcription–PCR for ERa was performed on 121 cases
with known ERa immunohistochemistry status. There was a
significant association between the two techniques (Chi-square 47,
Po0.0005). For ERa RT–PCR-negative cases, the median expres-
sion of ERa by immunohistochemistry was zero. For ERa RT–
PCR-positive cases, median expression of ERa by immunohisto-
chemistry was 90% (Figure 3). The proportion of immunostained
cells was significantly higher in cases positive for ERa by RT–PCR
(both T-test and Mann–Whitney Po0.0005).
Both RT–PCR and immunohistochemistry were assessed
for ERb1 in 101 cases (Table 4). No significant relationship
was identified between RT–PCR and immunohistochemistry
(Chi-square 0.8, P¼0.78). This was true for all ERb1 immuno-
histochemical cutoffs tested. There was no significant asso-
ciation between ERa RT–PCR and ERb1 immunohistochemistry
Actin
HPRT
Actin
ER 
ER 1
S MMNN
MMTT
MMNNS
S
S
S
NN TTS
NNS
299 bp
476 bp
367 bp
610 bp
610 bp
Figure 1 Reverse transcription–PCR analysis of ERa,E R b, actin and HPRT. Oestrogen receptor a and actin PCR were performed as a duplex (top) and
all other PCRs as single reactions. Controls included were cDNA negative reactions (N), MCF-7 cDNA (M) and testis cDNA (T). All samples were run on
agarose gels with PhiX174/HaeIII DNA size markers (S).
Table 4 Relationships between ERa and ERb1 as assessed by immunohistochemistry (IHC) and RT–PCR
ERa IHC
A neg. pos. Chi-square (P)
ERb1 IHC neg. 4 16 1.6 (0.21)
pos. 40 77
ERa RT–PCR
B neg. pos. Chi-square (P)
ERa IHC neg. 33 12 47 (o0.0005)
pos. 9 67
ERb1RT-PCR neg. 23 18 12 (o0.0005)
pos. 21 65
ERb1 IHC neg. 3 8 0.23 (0.64)
pos. 31 59
ERb1RT–PCR
C neg. pos. Chi-square (P)
ERa status neg. 20 25 4.9 (0.027)
pos. 19 57
ERb1 IHC neg. 4 7 0.08 (0.78)
pos. 29 61
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between ERb1 RT–PCR and positive ERa immunohistochemical
status (Chi-square 4.0, P¼0.027), the mean ERa scores were not
significantly different in ERb1 RT–PCR-negative and -positive
cases (45 and 55%, respectively, T-test P¼0.25).
Relationship between ER immunohistochemistry and
other parameters
Oestrogen receptor a expression, determined by immunohisto-
chemistry, was associated with PgR status and Ki67 status
(Table 5). Mean PgR staining was significantly higher in ERa-
positive cases (37 vs 4.7%, T-test Po0.0005), while the mean Ki67
was significantly lower (16 vs 47%, T-test Po0.0005). Positive ERa
status was also associated with low-stage, low morphological grade
and negative nodal status. No association between ERa status and
tumour size or lymphovascular invasion was revealed.
No significant association was detected between ERb1 immu-
nohistochemical expression and grade of tumour, axillary nodal
status, ERa status or PgR status. There was an association with
greater proliferation, measured by Ki67 staining. The mean %
Ki67-positive cells was greater (T-test P¼0.043) in the ERb1-
positive cases (28%) than in the ERb1-negative cases (18%). This
was true even when considering ERa-negative cases, but not ERa-
positive cases; Ki67 is greater (T-test P¼0.022, Mann–Whitney
P¼0.028) in ERb1-positive/ERa-negative cases (mean 51%) than
in ERb1-negative/ERa-negative cases (mean 18%). Using a median
cutoff of 60% (but not a cutoff at 20%), there was a trend for the
presence of lymphovascular invasion and larger tumours in ERb1-
positive cases, as seen for RT–PCR.
Relationship between ER RT–PCR and other parameters
While there was no relationship between ERb1 RT–PCR status and
Ki67 staining and only a trend for an association with PgR, there
was an association (Figure 4, Table 5) between these parameters
and ERa RT–PCR status. Oestrogen receptor a RT–PCR-positive
Figure 2 Immunohistochemical staining with ERb1 antibody. In normal
breast (A), a strong nuclear staining of the majority of luminal cells is seen
and the myopeithelial cells and stromal cells also express the protein.
Examples of invasive ductal carcinoma of no special type show either strong
nuclear expression with some cytoplasmic staining (B) or staining of only a
few positive cells (C).
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Figure 3 Boxplots of immunohistochemistry data (% immunopositive
cells) for ERa,E R b1, PgR and Ki67 categorised by RT–PCR results (left) or
IHC results (right) for ERa and ERb1. The box represents the interquartile
range, the line across the box indicates the median and the whiskers extend
from the box to the highest and lowest values (excluding outliers and
extreme points). Square, black markers represent outliers and extreme
points.
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(36% compared to 13% in negative cases, T-test Po0.001, n¼110)
and lower mean Ki67 (19% compared to 41% in negative cases, T-
test Po0.0005, n¼109). The relationships between ERa RT–PCR
and either PgR or Ki67 remain largely unchanged (Figure 3),
irrespective of ERb1 RT–PCR status, although Ki67 levels are
somewhat higher in ERb1-positive/ERa-negative cases. As ex-
pected from their ERa status, such tumours had significantly
higher Ki67 values and lower PgR values than either ERa-positive
subgroup (T-test Po0.04, Mann–Whitney Po0.007), but values
for these markers were not significantly different from the ERb1-
negative/ERa-negative subgroup (T-test and Mann–Whitney
P40.08).
Demonstration of ERa expression by RT–PCR was significantly
associated with low stage and low grade. There was a trend with
nodal status, but no association with size or lymphovascular
invasion. No relationship between ERb1 RT–PCR and stage, grade
or nodal status was identified, although associations with
lymphovascular invasion and larger tumours were detected
(Table 5).
Cases that were ERb1-positive/ERa-negative by RT–PCR had
larger tumours (mean 4.1cm) than those that were ERb1-positive/
ERa-positive (2.7cm, T-test Po0.0005), ERb1-negative/ERa-nega-
tive (2.2cm, T-test P¼0.001) or ERb1-negative/ERa-positive
(3.1cm, Mann–Whitney P¼0.012). These ERb1-positive/ERa-
negative tumours were also of higher stage than the other three
subgroups defined by RT–PCR (Mann–Whitney Po0.017).
Relationship between ER and disease outcome
In order to examine the possible effect of ERb1 status in a cohort
of patients receiving the same endocrine treatment, outcome data
have been restricted to those 143 women receiving adjuvant
Tamoxifen, but without primary endocrine treatment and no
primary or adjuvant chemotherapy. In this cohort, ERa expression
determined by immunohistochemistry (Figure 4), stage, grade,
size, nodal status, Ki67 staining and PgR were all associated with
the expected manner that measures of breast cancer relapse-free
survival (RFS) and demonstrated significant differences in breast
cancer-associated survival (BCS) and overall survival (OS). All
these markers had significant log-rank scores for RFS, BCS and OS
(all log-rank Po0.021). Lymphovascular invasion only exhibited a
Table 5 Relationship between ERa,E R b and other histopathological variables
Factor ERa IHC ERa RT–PCR ERbIHC ERb RT–PCR
Stage low P¼0.019 low P¼0.014 n.s. n.s.
(MW) n¼160 (MW) n¼127 (CS, MW) n¼138 (CS, MW) n¼127
Grade low Po0.0005 low Po0.0005 n.s. n.s.
(MW) n¼160 (MW) n¼127 (CS, MW) n¼138 (CS, MW) n¼127
Size n.s. n.s. larger P¼0.076* larger P¼0.025
(CS, MW) n¼158 (CS, MW) n¼125 (MW) n¼136 (MW) n¼125
Nodal status negative P¼0.048 negative P¼0.057 n.s. n.s.
(CS) n¼131 (CS) n¼108 (CS) n¼110 (CS) n¼108
Lymphovascular Invasion n.s. n.s. present P¼0.067* present P¼0.043
(CS, MW) n¼159 (CS) n¼126 (CS) n¼137 (CS) n¼126
PgR positive Po0.0005 positive Po0.0005 n.s. positive P¼0.056
(MW) n¼146 (CS) n¼110 (CS, MW) n¼138 (CS) n¼110
Ki67 low Po0.0005 low Po0.0005 high P¼0.034 n.s.
(MW) n¼141 (CS) n¼108 (MW) n¼133 (CS, MW) n¼108
Statistical test used was chi-square (CS), Mann-Whitney (MW); n.s.¼not significant. *using a cut-off of 60% positive cells for ERb1.
Figure 4 Kaplan–Meier RFS curves for ERa status (A), ERa RT–PCR
(B), ERb1 IHC (C) and ERb1 RT–PCR (D). Dotted lines are negative
cases and unbroken lines positive cases, crosses represent censored data, P-
values are given for log-rank tests.
1.0
0.8
0.6
0.4
0.2
1.0
0.8
0.6
0.4
0.2
1.0
0.8
0.6
0.4
0.2
1.0
0.8
0.6
0.4
0.2
40 80
Follow-up (months)
120
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
P = 0.0002
pos. n = 89
ER  IHC
neg. n = 44
P = 0.016
pos. n = 66
neg. n = 39
P = 0.090
pos. n = 101
ER 1 IHC
neg. n = 17
P = 0.65
pos. n = 67
ER 1RT−PCR
ER  RT−PCR
neg. n = 38
A
B
C
D
ERb1 in Tamoxifen-treated breast cancer
PA O’Neill et al
1699
British Journal of Cancer (2004) 91(9), 1694–1702 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ytrend for poorer outcome (P¼0.08 for RFS, P¼0.09 for BCS). In
multivariate analysis, ERa immunohistochemistry status was
independently significant for RFS in the presence of each other
parameter apart from grade and Ki67 status. Considering multiple
parameters, the strongest significance was attached to nodal status,
followed by grade.
Positive ERa immunohistochemical scores were associated with
better RFS using all cutoff points from the standard 10–90%
positive cells (Po0.001). Positive ERa RT–PCR status was
associated with a better outcome, as measured by RFS (Figure 4),
but not BCS (P¼0.055) or OS (P¼0.21). No significant
association with outcome was seen for ERb1 RT–PCR (Figure 4;
P¼0.65 RFS, P¼0.27 BCS, P¼0.87 OS). There was a trend for
better survival in cases immunohistochemically negative for ERb1
(Figure 4C). Only four of the 17 (24%) ERb1-negative cases
relapsed, when compared to 51 of 103 (50%) ERb1-positive cases
(Fisher’s exact test, P¼0.029). This was not true for any other
cutoff tested.
Within the adjuvant Tamoxifen cohort, 91 cases were ERa-
positive by immunohistochemistry and therefore typical of those
women who are likely to receive adjuvant endocrine treatment
today. Within this subgroup grade, nodal status and Ki67 were all
significant markers of outcome (RFS, BCS and OS all log-rank
Po0.01), as were stage (RFS log-rank Po0.01, BCS P¼0.03), PgR
(BCS, RFS and OS all log-rank Po0.05) and size (OS log-rank
P¼0.015). ERb1 RT–PCR showed no association with any
measure of outcome, but as before a trend for a worse outcome
in ERb1 immunohistochemically positive cases was seen (RFS, log-
rank P¼0.11; Fisher’s exact test, P¼0.061).
DISCUSSION
This study has confirmed the initial hypothesis that comparison of
protein expression levels for ERa and ERb1, together with their
respective mRNA levels, are indicators of the clinical and
pathological characteristics of a cohort of postmenopausal primary
breast cancer patients treated only surgically and thereafter with
Tamoxifen therapy. The findings confirm the differential expres-
sion of these two oestrogen receptors by human breast carcinomas,
with a high degree of correlation between the immunohistochem-
ical and RT–PCR data for ERa being identified.
Unlike the findings for ERa, this study did not reveal a strong
correlation between ERb RT–PCR and the corresponding
immunohistochemistry. Identification of the technical and biolo-
gical reasons for this apparent discrepancy is of fundamental
importance to understanding the role of ERb in human breast
cancer. Recently, Omoto et al (2002) reported that protein and
RNA levels are often not in agreement, but did not provide any
cogent explanation for this discrepancy. Three potentially
important factors require consideration: First, this apparent
discrepancy might be explained by relative lack of sensitivity of
RT–PCR when compared to the 20% immunohistochemical cutoff
(where 29% of cases were RT–PCR negative and immunohisto-
chemically positive). Previously, it has been reported that mRNA
levels for ERb are lower and more diverse than those for ERa (Iwao
et al, 2000) and that levels of ERb1 are lower than for other ERb
variants (Leygue et al, 1999; Iwao et al, 2000). Either of these
phenomena would contribute to a lower sensitivity for detection of
ERb1 by RT–PCR. When testing for a possible correlation between
ERb1 identified by RT–PCR and by immunohistochemistry,
various cutoff levels were assessed. However, there was no value
that gave a statistically significant association with the RT–PCR
data. In contrast, correlations occurred between ERb1 RT–PCR
and with both ERa immunohistochemistry and RT–PCR, which
were not recapitulated at the protein level and which would
account for other reports of relationships between the two ERs.
Second, while immunohistochemistry is an in situ technique in
which data are obtained subjectively, RT–PCR is performed on
disaggregated tissue preparations in a quantitative manner. Hence,
expression of ERb1 mRNA from other cell types might account for
the seven cases that were RT–PCR positive and immunohisto-
chemically negative, but not the 29 RT–PCR-negative but
immunohistochemically positive cases. While a theoretical possi-
bility, this explanation is interesting since nonepithelial stromal
cells of normal breast tissues have been found to be weakly ERb-
positive while stromal cells of the unusual phylloides tumours were
found to strongly express ERb (Shaaban et al, 2003b).
Translational or post-translational control mechanisms are
likely to play a significant role in ERb expression in some cases
of breast cancer. We have already shown that modulation of ERs is
both complex and indirect, the latter mechanisms including altered
expression of homeostatic protein hsp-27 (O’Neill et al, 2003). It is
now recognised that the precise structure of many proteins
expressed by individual genes varies with the phenotypic status of
an individual cell. These ‘splice variants’, while encoded within the
normal genome, become expressed according to the overall status
of the tissue in which they originate (e.g. embryonic, adult-
proliferative or malignant). Such differences are already recog-
nised to be important, with respect to splice variants of some
proteins (e.g. voltage-gated ion channels), but are yet to be proven
for others (e.g. ERs), although there is substantial circumstantial
evidence for this selection. If splice variation is an important factor
in the expression of ERb, then use of monoclonal antibodies
directed to epitopes in the wild type that become spliced out and
hence nonexpressed in the cancers provide erroneous information.
Recognition of this caveat is important for accurate interpretation
of such data. Multiple forms of ERb splice variants occur in normal
breast tissue and breast malignancies (Leygue et al, 1999; Omoto
et al, 2002). Unfortunately, most previous RT–PCR analysis
studies have used primers unsuitable for distinguishing individual
isoforms. Recent production of antibodies suitable for detection of
individual ERb isoforms (Saunders et al, 2002; Skliris et al, 2002)
should allow a better understanding of the complex factors
regulating hormone responsiveness of human breast carcinomas
to emerge (O’Neill et al, 2003; Shaaban et al, 2003b).
In the current series, and in accordance with previous
immunohistochemical reports (Enmark et al, 1997), ERb1 was
predominantly localised to the nuclei of epithelial cells and of
myoepithelial cells, as well as stromal cells (Taylor and Al-Azzawi,
2000; Speirs et al, 2002). Oestrogen receptor b1 expression was
identified in 85% of invasive cancers using a 20% immunohisto-
chemical cutoff and the median expression was 60%. The reported
proportion of ERb1-positive invasive carcinomas varies appreci-
ably among previous studies and might be explained by differences
in the specificity of the antibodies, methods of antigen retrieval
and different thresholds used to define positive staining (Skliris
et al, 2002; Shaaban et al, 2003a). In the current cohort, 56% of
cancers were positive for both ERa and ERb1 by immunohisto-
chemistry, while 29% of cancers were ERa-negative and ERb1-
positive. Given the potential discrepancies due to antibody usage
and staining technique, together with the robust levels of ERb1
staining, these numbers are in agreement with those reported in
other immunohistochemical studies of ERb1 (Jarvinen et al, 2000;
Omoto et al, 2002; Saunders et al, 2002), which describe 48–74%
of cases as ERb1-positive/ERa-positive and 8–20% as ERb1-
positive/ERa-negative. Unlike ERa, which is usually expressed in
only a minority of cells in normal epithelium and aberrantly
expressed at high levels in the majority of cells in many breast
cancers, ERb1 is apparently expressed in the majority of cells in
normal breast and this expression is maintained in most breast
cancers at a variety of levels. Persisting but varied expression of
ERb1 in the presence or absence of greater amounts of ERa
indicates that the role played by the interaction between ERa and
ERb1 during mammary carcinogenesis and in subsequent cancers
is likely to be complex. Thus, this study has pinpointed a cellular
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ycontrol mechanism that, in human breast cancer, requires specific
and detailed analysis.
Only one previous study has reported ERb immunohistochem-
istry in adjuvant Tamoxifen-treated patients (Mann et al, 2001). In
contrast to our present findings, the previous adjuvant study
suggested ERb-positive patients to have a better survival when
compared with ERb-negative patients. Overall, the immunostain-
ing reported in the previous study appeared weaker than observed
here, with only 66% of 118 cases being ERb-positive at a 10%
cutoff, when compared to 85% positive for ERb1 at a 20% cutoff.
Since that study utilised an antibody with broad specificity,
possible contribution of other ERb variants is unclear. It is
possible that the findings of that study are due to expression of
variants ERb2 and ERb5 since, at the RNA level, these have been
shown to be greater than ERb1 in breast cancers (Leygue et al,
1999; Omoto et al, 2002). The isoform of ERb to have the greatest
effect on outcome for breast cancer patients is yet to be confirmed.
Although only seen here for RT–PCR, others have reported some
association between ERa and ERb staining (Jarvinen et al, 2000;
Omoto et al, 2001) and it is possible that the unreported ERa status
of the cases previously reported has some influence on the data
(Mann et al, 2001). In this study, no association was found between
ERb and grade of tumour, progesterone receptor, or nodal status,
thus broadly in agreement with other studies. However, in this
cohort of post-menopausal women treated with Tamoxifen
therapy, ERb-positive cancers tended to have poorer RFS than
ERb-negative cancers. This finding was not entirely due to the
presence of ERb in some ERa-negative cases, since a trend was still
present in the ERa-positive subgroup.
This study lends some support to the original hypothesis that
expression of wild-type ERa influences the effectiveness of
antioestrogen therapy. Furthermore, antioestrogens (e.g. Tamox-
ifen) of particular affinity for the specific splice variant of
oestrogen receptor expressed by each individual breast carcinoma
may have agonistic effects in ERb-positive tumours, hence
resulting in a lack of efficacy of hormonal therapy (Speirs et al,
1999). There is evidence that this might also be true for ERb2, since
this protein was associated with poor response to Tamoxifen in a
neoadjuvant setting (Saji et al, 2002). However, our data contradict
less critical reports that are imprecise with respect to patient
groups examined and ERb variants detected. Further studies are
now being performed to clarify the roles of different ERb splice
variants in breast cancers treated by hormonal manipulation.
These will include cohorts of patients selected according to clinical
and treatment criteria in order to determine the importance of ERb
in breast cancer management and outcome.
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